Skip to main content

Residual Pure Intralymphatic Breast Carcinoma After Neoadjuvant Therapy: Clinicopathologic Analysis and Comparative Outcomes Across Published Studies

In brief

Eight of 13 node-negative cases had residual tumor missed by ypT0 staging

In this rare pattern, tumor remains only in lymphatic or blood vessels after treatment, without invading breast tissue. All 13 patients were staged ypT0, but measuring the vessel-contained tumor suggested residual cancer burden above zero in 8 node-negative patients; survival was high in this small cohort. The authors propose a staging modifier and reporting field, but their clinical value needs study.

Journal
Archives of pathology & laboratory medicine (Q1)
Published
29 October 2026
Study design
Retrospective cohort
Evidence level
Level 3, Low (CEBM 3b)
Authors
Hisham F Bahmad, Elena F Brachtel, Merce Jorda, Carmen Gomez-Fernández, Youley Tjendra
PMID
43042959
DOI
10.5858/arpa.2026-0182-OA

Why clinicians should know about it

  • Picked for Pathology and Forensic Medicine (top studies of the week, 22 November 2026): Residual tumor classification, staging mismatch, and proposed reporting changes

Abstract

CONTEXT.—: Residual pure intralymphatic carcinoma (PIC), defined as residual tumor confined exclusively to lymphovascular spaces without stromal invasion after neoadjuvant therapy (NAT), is a rare, residual disease pattern. No standardized staging, pathology reporting protocol, or consensus classification exists within current frameworks. OBJECTIVE.—: To characterize the clinicopathologic features, post-NAT staging, Residual Cancer Burden (RCB) classification, and outcomes of patients with PIC at our institution, and to perform a pooled analysis of all published cohorts. DESIGN.—: This is a retrospective cohort study of consecutive patients with breast cancer treated with NAT and surgery at a large academic medical center from January 2015 to September 2025. Identified PIC cases were systematically characterized and compared against 5 previously published cohorts. RESULTS.—: Of 2000 patients screened, 13 (0.65%) had PIC (9 of 13 [69%] grade 3; 7 of 13 [54%] human epidermal growth factor receptor 2 [HER2]-positive). All had ypT0 disease (yp denotes pathologic stage after neoadjuvant therapy) on American Joint Committee on Cancer (AJCC) staging, while 8 of 13 node-negative patients (62%) may have an RCB score of RCB-I or higher when intralymphatic tumor dimensions are entered-a framework mismatch rather than true pathologic complete response (pCR). At median follow-up of 59.2 months, overall survival was 100% (13 of 13) and disease-free survival, was 92% (12 of 13). Pooled analysis (N = 60) showed mortality decline from 83% (5 of 6) in the earliest (pre-2018) cohort to 0% to 20% post-2018. CONCLUSIONS.—: Current staging frameworks may misclassify PIC as pCR, implying incomplete standardization with potential clinical consequences. We propose an AJCC modifier, ypT0(LVI+), for residual lymphovascular invasion in the absence of residual in situ carcinoma or nodal metastasis, plus a dedicated College of American Pathologists synoptic field to ensure appropriate management.

Abstract as published, via PubMed.

View on PubMedFull text at the publisherOpen in the app

For healthcare professionals. The summary is generated by AI from the published abstract, and the evidence level is assigned automatically from the study design on the Oxford CEBM hierarchy. Neither is medical advice. Read the full paper before changing practice.